Program
tobevibart
Also written as “VIR-3434” and “Tobevibart”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis · Fibrosis · Hepatitis D, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vir Biotechnology | 84 open or running | phase 3since Mar 24, 2025 | May 25, 2020 | Nov 2026phase 2 · NCT07142811 |
| Virion Therapeutics | 10 open or running | phase 1since Sep 20, 2023 | Sep 20, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 25, 2020First study: phase 1 study in Hepatitis B, ChronicNew to Vir BiotechnologyVir Biotechnology · NCT04423393 · 113 enrolled · Germany, Hong Kong, Korea, Republic of and more
- Apr 21, 2021Phase 2 study in Hepatitis B, ChronicVir Biotechnology · NCT04856085 · 244 enrolled · United States, Canada, Germany and more
- Jul 1, 2022Phase 2 study in Hepatitis D, ChronicVir Biotechnology · NCT05461170 · 95 enrolled · Bulgaria, France, Germany and more
- Jul 15, 2022Phase 1 study in FibrosisVir Biotechnology · NCT05484206 · 88 enrolled · United States
- Nov 3, 2022Phase 2 study in Hepatitis B, ChronicVir Biotechnology · NCT05612581 · 33 enrolled · France, Hong Kong, Moldova and more
- Sep 20, 2023Virion Therapeutics's first study: phase 1 study in Hepatitis B, ChronicNew to Virion TherapeuticsVirion Therapeutics · NCT06070051 · 35 enrolled · Hong Kong, New Zealand
- Mar 24, 2025Phase 3 study in HepatitisVir Biotechnology · NCT06903338 · 124 enrolled · United States, Canada, Georgia and more
- Aug 13, 2025Phase 3 study in HepatitisVir Biotechnology · NCT07128550 · 150 enrolled · Austria, France, Germany and more
- Aug 19, 2025Phase 2 study in HepatitisVir Biotechnology · NCT07142811 · 100 enrolled · Belgium, Bulgaria, France and more
Ahead
- Nov 2026Primary completion: phase 2 study in HepatitisVir Biotechnology · NCT07142811
- Dec 2026Primary completion: phase 3 study in HepatitisVir Biotechnology · NCT07128550
- Nov 2031Primary completion: phase 2 study in Hepatitis D, ChronicVir Biotechnology · NCT05461170
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07142811Hepatitis · Belgium, Bulgaria, France and more | 2 | Active, not recruiting | Vir Biotechnology | Nov 2026 | 100 |
| NCT07128550Hepatitis · Austria, France, Germany and more | 3 | Active, not recruiting | Vir Biotechnology | Dec 2026 | 150 |
| NCT06903338Hepatitis · United States, Canada, Georgia and more | 3 | Active, not recruiting | Vir Biotechnology | Sep 30, 2026 | 124 |
| NCT06070051Hepatitis B, Chronic · Hong Kong, New Zealand | 1 | Completed | Virion Therapeutics | Mar 31, 2026 | 35 |
| NCT05612581Hepatitis B, Chronic · France, Hong Kong, Moldova and more | 2 | Completed | Vir Biotechnology | Oct 15, 2024 | 33 |
| NCT05484206Fibrosis · United States | 1 | Completed | Vir Biotechnology | Dec 9, 2025 | 88 |
| NCT05461170Hepatitis D, Chronic · Bulgaria, France, Germany and more | 2 | Active, not recruiting | Vir Biotechnology | Nov 2031 | 95 |
| NCT04856085Hepatitis B, Chronic · United States, Canada, Germany and more | 2 | Completed | Vir Biotechnology | Mar 16, 2026 | 244 |
| NCT04423393Hepatitis B, Chronic · Germany, Hong Kong, Korea, Republic of and more | 1 | Completed | Vir Biotechnology | Oct 24, 2022 | 113 |
How it is read
Names in the registry
- “VIR-3434”, 6 entries
- “Tobevibart”, 3 entries
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 4 studies
- Hepatitis, 3 studies
- Fibrosis, 1 study
- Hepatitis D, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.